We’re an established health economics and outcomes consultancy that anticipates your needs and exceeds your expectations

Recent activities

Market access: budget impact analysis
What is a budget impact analysis? Pressure on healthcare insurers to fund the best available care while keeping within budgetary constraints has...
When is a simple model enough? How to handle structural uncertainty in cost-effectiveness models.
Sam Bryning, intern at Symmetron: 'formally accounting for structural uncertainty in cost-effectiveness models makes research and decision making...
Health economic modelling: a guide for pharmaceutical and medical device companies
Health economic modelling is a process for synthesising and comparing the costs and benefits of new (proposed) and existing medicines or devices in...
Evidence generation and communication in drug development
Clinical evidence generation: clinical trials Health researchers continually discover new evidence that deepens our understanding of disease...

🏅Our poster was ranked top 5% at ISPOR Europe 2021 🏅

The overall survival (OS) is the main efficacy outcome considered by HTA agencies, including NICE, when assessing immuno-oncology therapies. How can robust OS extrapolation aid reimbursement success?

What does it take to secure reimbursement for new immuno-oncological treatments in the UK?

We have investigated this topic in our submission to ISPOR Europe 2021.

What's the best value approach to treating drug-resistant epilepsy?

We have investigated this topic in our submission to ISPOR Europe 2021.

How can patient-reported outcomes impact regulatory approval and reimbursement for new drugs?

We have investigated this topic in our submission to ISPOR Europe 2021.

Economic value of insertable cardiac monitors in unexplained syncope in the United States

We’re excited to have co-authored a publication in the BMJ Open Heart Journal assessing the cost-effectiveness of a novel diagnostic device. 

Assessing the quality and coherence of network meta-analyses of biologics in plaque psoriasis: what does all this evidence synthesis tell us?

We’re thrilled to have co-authored a publication in Dermatology and Therapy to appraise and synthesise the published evidence on biological therapies for plaque psoriasis. 

Outcomes-based contracts for medicines in Europe

Are you interested in outcomes-based contracts? Click below to learn more about our work on European healthcare systems and challenges in planning and implementation.

Vagus nerve stimulation for drug-resistant epilepsy patients in England

We’re excited to have published an economic evaluation of this innovative device. 

Our work in numbers

43

total clients

28

billion USD – average client turnover

67

% of work conducted with global HQ

Our story

We discover and drive innovative solutions to bring lifesaving treatments to patients around the world.

We work with our clients as a trusted partner and critical friend. Hence our name, Symmetron, from the Greek sym (together) and metron (calculate).

Since 2008, we have been growing steadily in size and capability into a highly-respected source of research in health economics and health outcomes.

Find out more about our successes 

We discover and drive innovative solutions to bring lifesaving treatments to patients around the world.

We work with our clients as a trusted partner and critical friend. Hence our name, Symmetron, from the Greek sym (together) and metron (calculate).

Since 2008, we have been growing steadily in size and capability to a highly-respected source of research in health economics and health outcomes.

Find out more about our successes